Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 4;34(10):1514-1531.e7.
doi: 10.1016/j.cmet.2022.08.003. Epub 2022 Aug 25.

Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation

Affiliations
Free article

Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation

Chi Kin Wong et al. Cell Metab. .
Free article

Abstract

Gut intraepithelial lymphocytes (IELs) are thought to calibrate glucagon-like peptide 1 (GLP-1) bioavailability, thereby regulating systemic glucose and lipid metabolism. Here, we show that the gut IEL GLP-1 receptor (GLP-1R) is not required for enteroendocrine L cell GLP-1 secretion and glucose homeostasis nor for the metabolic benefits of GLP-1R agonists (GLP-1RAs). Instead, the gut IEL GLP-1R is essential for the full effects of GLP-1RAs on gut microbiota. Moreover, independent of glucose control or weight loss, the anti-inflammatory actions of GLP-1RAs require the gut IEL GLP-1R to selectively restrain local and systemic T cell-induced, but not lipopolysaccharide-induced, inflammation. Such effects are mediated by the suppression of gut IEL effector functions linked to the dampening of proximal T cell receptor signaling in a protein-kinase-A-dependent manner. These data reposition key roles of the L cell-gut IEL GLP-1R axis, revealing mechanisms linking GLP-1R activation in gut IELs to modulation of microbiota composition and control of intestinal and systemic inflammation.

Keywords: GPCR; NASH; T cells; diabetes; glucagon-like peptide 1; immunology; inflammation; intestinal intraepithelial lymphocytes; microbiota; obesity.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests D.J.D. has served as a speaker or consultant for Altimmune, Amgen, AMT Inc., Eli Lilly Inc., Kallyope Inc., Merck Inc., Novo Nordisk Inc., and Pfizer Inc. R.J.S. serves as a paid consultant for Novo Nordisk, Scohia, Fractyl, and ShouTi. R.J.S. has equity positions in Calibrate and Rewind Health.

Publication types

Grants and funding